[ Inside the business ]

SOLV stock analysis

SOLV · Solventum Corp

Surgical and medical instruments and apparatus. Shrinking 7%. Keeps 6¢ of every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 0.7× sales in 5 yrs. Evidence: sales −7% · 6¢ profit/$1.

01 What's priced in?0.7× sales in 5 yrs
Sales now$8.2B
Needed in 5 yrs$5.8B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales −7%, slowing
No customer over 10%
Prepaid $596MSales −7%, slowing
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 6¢ per $1, falling
'22'23'24'256¢
Before running costs: 58% → 53%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares +0.7%/yrDebt $5.1B
07 What could break it?1 to watch
  • Growth peaked

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth −3%, +2%, then −7% vs. a year ago.

What could go wrong

Few warning signs.

Debt is heavy.

Speculative check

Not classified.

Not Self-funding because of: loss in the latest quarter, debt over 4× operating profit.

What they sell

75% Product.

Product 75% · Cost Of Software And Rentals 25%

Where each dollar goes

6¢ profit.

45¢ to make what it sells, 50¢ on research and overhead, 6¢ left over. Revenue $8.2B in the last 12 months.

Its market

0.3× the economy.

The government expects its industry, fabricated metal product manufacturing, to grow 0.7% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Some warning signs.

A few of its numbers drift toward the pattern of past manipulators. Cash covers 199¢ of each $1 of profit.

Competitive advantage

3 of 4 years.

Returns beat its 8.4% cost of capital in 3 of the last 4 years. Gross margin went from 58% to 53%.

Future bets

9% on research.

$723M a year on R&D. $310M on equipment and buildings.

All figures from Solventum Corp's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.